McKesson Ventures has hired Michelle Snyder as its newest investment partner.
Snyder, a mobile health pioneer, is known for her leadership and guidance in building Epocrates, one of the healthcare industry’s first successful mobile health companies. She brings more than 25 years of healthcare experience to the McKesson Ventures team and will support investments in healthcare technology and services companies. Snyder’s hire also expands the number of female partners at McKesson Ventures, underscoring the firm’s commitment to diversifying its leadership team.
Prior to joining McKesson Ventures, Snyder served as chief marketing officer for Welltok, a consumer health activation company. She was previously a member of the digital health investment team at InterWest Partners and served in a variety of advisory roles for numerous early- and late-stage digital health technology companies and healthcare incubators.
“Michelle’s deep operating experience with venture backed health technology businesses provides our team and our portfolio companies with valuable, strategic guidance,” said Dave Schulte, senior vice president and managing director at McKesson Ventures. “Michelle joins a deep bench of talented and diverse leaders and will bring a unique point of view to the table.”
“With the convergence of new technologies, advanced analytics, innovative payment models and consumerism, now is the time to invest in healthcare innovation,” said Snyder. “Joining the McKesson Ventures team means helping innovative, high-growth companies meet their full potential. The future of healthcare will be determined by their success and we’re here to help them.”
Snyder joins the McKesson Ventures team after the exits of several portfolio companies including Accolade, Amwell, and GRAIL. McKesson Ventures will continue to expand its leadership, presence, and expertise in oncology care, consumer health, digital pharmacy, biopharma clinical and commercial services, data and analytics, and value-based care.
Read the full press release here.